Shah, V
,
Sherborne, A L
Walker, B A http://orcid.org/0000-0002-8615-6254
Johnson, D C http://orcid.org/0000-0003-0887-3343
Boyle, E M
Ellis, S
Begum, D B
Proszek, P Z
Jones, J R
Pawlyn, C http://orcid.org/0000-0002-7190-0028
Savola, S
Jenner, M W
Drayson, M T
Owen, R G
Houlston, R S
Cairns, D A http://orcid.org/0000-0002-2338-0179
Gregory, W M
Cook, G
Davies, F E
Jackson, G H
Morgan, G J
Kaiser, M F
Article History
Received: 1 March 2017
Revised: 11 May 2017
Accepted: 25 May 2017
First Online: 6 June 2017
Competing interests
: Honoraria from Novartis, Pfizer, Takeda, Janssen by EMB; research support from Celgene by JRJ; consultancy and honoraria from Celgene, Novartis, Takeda by CP; SS was employed by MRC Holland; Honoraria and consultancy from Janssen, Novartis, Amgen, Takeda, Celgene by MWJ; Research funding: Janssen, Celgene; employment, equity ownership, royalties from Abingdon Health/Serascience by MTD; honoraria, consultancy from Celgene, Takeda, Janssen by RGO; Research funding from Celgene by DAC; Research Funding from Celgene by WMG; consultancy and research funding from Janssen, Celgene, Takeda Oncology, Sanofi, Amgen and BMS by GC; honoraria from Takeda-Millenium, Onyx/Amgen, Celgene and Janssen by FED; GHJ: honoraria and consultancy from Celgene, Takeda, MSD, Janssen, Roche andAmgen; research funding and travel support from Celgene and Takeda; honoraria, consultancy, research funding from Celgene, Takeda-Millennium, BMS by GJM; honoraria from Amgen, Celgene, Janssen: Consultancy for Takeda, Amgen, Chugai Pharma, BMS, Janssen; Research Funding from Celgene by MFK. The remaining authors declare no conflict of interest.